<DOC>
	<DOCNO>NCT02885441</DOCNO>
	<brief_summary>Patients acute pancreatitis randomly assign either study group receive oral Ketorolac control group ( double blind study ) .</brief_summary>
	<brief_title>Treatment Acute Pancreatitis With Ketorolac</brief_title>
	<detailed_description>Patients acute pancreatitis randomly assign either study group control group ( double blind study ) . - The study group receive oral Ketorolac - The control group receive placebo Ketorolac administrate three time daily mouth start time admission first three day hospitalization ( 72 hour ) . Hs-CRP measured admission addition standard laboratory tests.It do every day 5 day , administration study drug till time discharge whichever occur early . Patients follow organ failure involvement duration hospitalization . The study continue gather clinical follow information four month .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>1 . Predicted Severe Acute Pancreatitis 2 . Enrollment within 72 hour diagnosis 3 . Obtaining informed consent 4 . Age &gt; 18 year 1 . Heart disease , Hypertension 2 . Hemorrhagic diathesis , Incomplete hemostasis , High risk bleed 3 . Lactating woman 4 . Pregnancy 5 . Advanced renal disease 6 . Hypersensitivity ketorolac , aspirin , NSAIDs 7 . Concurrent use aspirin , NSAIDs , probenecid , pentoxifylline 8 . Active history peptic ulcer disease 9 . Recent history GI bleed perforation 10 . Inflammatory bowel disease 11 . Severe hepatic impairment active hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Inflammation</keyword>
</DOC>